Hainan Shuangcheng Pharmaceut (002693) — Net Asset Quality Index
Hainan Shuangcheng Pharmaceut (002693) has a Net Asset Quality Index of 53.0% as of June 2026. This metric measures the proportion of total assets financed by shareholders' equity — total assets of CN¥810.55 Million minus total liabilities of CN¥381.09 Million yields net assets of CN¥429.45 Million. A higher index indicates a stronger, lower-leverage balance sheet. Read 002693 current and long-term liabilities for a breakdown of total debt and financial obligations.
Quality Index
Net Assets
Total Assets
Total Liabilities
Hainan Shuangcheng Pharmaceut Net Asset Quality Index Over Time (2009–2025)
This chart shows how Hainan Shuangcheng Pharmaceut's Net Asset Quality Index has evolved across 17 annual periods from 2009 to 2025. As of June 2026, the index stands at 53.0%, representing net assets of CN¥429.45 Million against total assets of CN¥810.55 Million CNY. For live market cap and overall valuation, see 002693 market cap.
Annual Net Asset Quality Index for Hainan Shuangcheng Pharmaceut (2009–2025)
The table below presents the year-by-year Net Asset Quality Index for Hainan Shuangcheng Pharmaceut from 2009 to 2025, covering 17 annual filings. Each row shows total assets, total liabilities, net assets, the quality index percentage, and the change in percentage points compared to the prior year. Check 002693 capital-intensive asset ratio to assess the company's strategic physical and investment asset allocation.
| Year | Quality Index | Net Assets (CNY) | Total Assets | Total Liabilities | Change (pp) |
|---|---|---|---|---|---|
| 2025 | 50.9% | CN¥420.53 Million | CN¥825.78 Million | CN¥405.25 Million | ▼ -1.6 pp |
| 2024 | 52.5% | CN¥411.61 Million | CN¥783.87 Million | CN¥372.26 Million | ▼ -11.9 pp |
| 2023 | 64.4% | CN¥517.65 Million | CN¥803.25 Million | CN¥285.60 Million | ▲ +0.7 pp |
| 2022 | 63.8% | CN¥580.94 Million | CN¥911.02 Million | CN¥330.08 Million | ▼ -2.6 pp |
| 2021 | 66.3% | CN¥566.75 Million | CN¥854.56 Million | CN¥287.80 Million | ▲ +0.4 pp |
| 2020 | 65.9% | CN¥598.31 Million | CN¥907.68 Million | CN¥309.37 Million | ▼ -5.4 pp |
| 2019 | 71.3% | CN¥678.26 Million | CN¥950.98 Million | CN¥272.72 Million | ▲ +11.5 pp |
| 2018 | 59.8% | CN¥669.69 Million | CN¥1.12 Billion | CN¥450.56 Million | ▲ +4.5 pp |
| 2017 | 55.3% | CN¥761.71 Million | CN¥1.38 Billion | CN¥615.41 Million | ▲ +7.9 pp |
| 2016 | 47.5% | CN¥553.13 Million | CN¥1.17 Billion | CN¥612.40 Million | ▼ -12.4 pp |
| 2015 | 59.8% | CN¥927.61 Million | CN¥1.55 Billion | CN¥622.56 Million | ▼ -34.9 pp |
| 2014 | 94.7% | CN¥893.55 Million | CN¥943.54 Million | CN¥49.99 Million | ▼ -0.2 pp |
| 2013 | 94.9% | CN¥870.62 Million | CN¥917.04 Million | CN¥46.42 Million | ▼ -0.5 pp |
| 2012 | 95.4% | CN¥845.85 Million | CN¥886.65 Million | CN¥40.80 Million | ▲ +3.4 pp |
| 2011 | 92.0% | CN¥228.23 Million | CN¥248.06 Million | CN¥19.83 Million | ▲ +29.6 pp |
| 2010 | 62.4% | CN¥157.82 Million | CN¥252.73 Million | CN¥94.92 Million | ▼ -17.2 pp |
| 2009 | 79.7% | CN¥77.95 Million | CN¥97.85 Million | CN¥19.91 Million | — |